The ability to eliminate specific pathologic cells is creating more options for multiple myeloma patients. Several targeting approaches are in development. BCMA is preferentially expressed on ...

Further, a comprehensive clinical development program has been started to study the use of cilta-cel in earlier lines of ... cancers. BCMA is highly expressed on myeloma cells and has been ...

We will incorporate innovations in CAR-T cell design and CRISPR-mediated transgene insertion to generate an improved BCMA CAR T cell therapy, enhancing safety, purity, potency, and persistence. This ...

Objectives This study aims to evaluate the safety and efficacy of BCMA-CD19 compound chimeric antigen receptor T cells (cCAR) to dual reset the humoral and B cell immune system in patients with ...

Amyloid light-chain (AL) amyloidosis is a devastating, rare plasma cell disorder that results in organ deposition. In the US, there are ~3,972 diagnoses every year. Currently, there is no cure for AL ...

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire ...

Patients had a median of three prior lines ... cell engager simultaneously targets BCMA, CD38, and CD3, enhancing tumor-specific cytotoxicity while minimizing off-target effects. "ISB 2001's dual ...

The top-line efficacy ... for squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the ...

The monoclonal antibody, which targets B-cell maturation antigen (BCMA ... enrolled in this study had access to BCMA therapy at subsequent lines of therapy," said Holstein, who was not involved ...